Expect near-term price weakness due to dilution. Watch for pricing details in the prospectus supplement and any updates on use of proceeds. The stock may find support if proceeds are allocated to promising pipeline catalysts.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 28 $73.99entry
- T+1 · 7mo ago −6.08%α −6.07% · $69.49
- T+5 · 7mo ago −10.18%α −11.87% · $66.46
- T+20 · 6mo ago −20.18%α −25.65% · $59.06
- T+60 · 4mo ago +24.27%α +20.28% · $91.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oruka Therapeutics announced a $500M underwritten public offering of common stock and pre-funded warrants, with an additional $75M option for underwriters. The proceeds will support its clinical-stage pipeline for psoriasis and inflammatory diseases. The offering represents roughly 15% dilution at current market cap, which is a negative signal for near-term stock price.
Key Financial Metrics
Key Facts
- $500M underwritten public offering of common stock and pre-funded warrants
- Underwriters have a 30-day option to purchase up to an additional $75M of shares
- Leerink Partners, TD Cowen, Goldman Sachs, Stifel, and Guggenheim Securities are joint bookrunning managers
- Shelf registration statement (Form S-3) became effective on April 10, 2026
- Offering size is approximately 14.7% of the $3.4B market cap
Financial Impact
Approximately $500M raised (up to $575M with greenshoe), diluting existing shareholders by ~14.7% at current market cap
Risk Factors
- Dilution of existing shareholders
- Offering may not close if market conditions deteriorate
- Clinical-stage biotech carries inherent pipeline risk
- Potential for further offerings as cash needs increase
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282035 |
Track record
40 reports on ORKA
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers